Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017152090) RECOMBINANT FOLLISTATIN-FC FUSION PROTEINS AND USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/152090 International Application No.: PCT/US2017/020723
Publication Date: 08.09.2017 International Filing Date: 03.03.2017
IPC:
C07K 14/47 (2006.01) ,A61P 21/00 (2006.01) ,A61K 38/17 (2006.01) ,A61K 38/22 (2006.01)
[IPC code unknown for C07K 14/47][IPC code unknown for A61P 21][IPC code unknown for A61K 38/17][IPC code unknown for A61K 38/22]
Applicants:
SHIRE HUMAN GENETIC THERAPIES, INC. [US/US]; 300 Shire Way Lexington, MA 02421, US
Inventors:
ISKENDERIAN, Andrea; US
NORTON, Angela W.; US
SHEN, Chuan; US
PAN, Clark; US
Agent:
CHEN, Fangli; US
BAUER, Steven; US
SHALEK, James; US
MCGOUGH, Kevin; US
COUSINS, Abigail; US
Priority Data:
62/303,95404.03.2016US
Title (EN) RECOMBINANT FOLLISTATIN-FC FUSION PROTEINS AND USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY
(FR) PROTÉINES DE FUSION FOLLISTATINE-FC RECOMBINANTES ET LEUR UTILISATION DANS LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
Abstract:
(EN) The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin fusion protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
(FR) La présente invention concerne, entre autres, des méthodes et des compositions permettant de traiter la dystrophie musculaire, en particulier, la dystrophie musculaire de Duchenne (DMD). Dans certains modes de réalisation, une méthode selon la présente invention comprend l'administration à un individu qui est atteint de DMD, ou qui est susceptible d'en être atteint, d'une quantité efficace d'une protéine de fusion recombinante de follistatine de sorte qu'au moins un symptôme ou une caractéristique de DMD soit réduit en termes d'intensité, de gravité, ou de fréquence, ou bien ait une apparition retardée.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)